Archives
-
MDL 28170: A Selective Calpain Inhibitor Workflow
2026-09-17
MDL 28170 combines cell permeability, brain access, and nanomolar inhibition of calpain and cathepsin B for mechanistic neuroprotection research. This workflow translates recent BDNF/TrkB findings into practical assay design while addressing formulation, target attribution, and cross-model validation.
-
Carvedilol Workflows for Receptor Research
2026-09-16
A practical guide to using Carvedilol in β-adrenergic receptor research, oxidative stress inhibition, vascular remodeling, and hematopoietic regeneration studies. The workflow emphasizes receptor-selectivity controls, solvent management, and the distinct risks of nonselective blockade after allogeneic transplantation.
-
MLKL Polymerization and Lysosomal Permeabilization
2026-09-16
This study identifies lysosomal membrane permeabilization as a key execution step in MLKL-driven necroptosis. By combining live-cell imaging with MLKL and cathepsin B perturbation, the authors show that MLKL polymers disrupt lysosomes, release cathepsin B, and accelerate cell death before plasma membrane rupture.
-
SIRT3-SUMO, Treg Differentiation, and Asthma
2026-09-15
The reference study identifies an SIRT3–SUMO–fatty acid oxidation axis that links cellular metabolism to N-glycosylation and regulatory T-cell differentiation in asthma. Its combination of transcriptomic analysis, an OVA-sensitized model, ex vivo T-cell differentiation, and molecular perturbation provides a mechanistic framework for understanding how Treg abundance may influence both Th2 and non-Th2 airway inflammation.
-
ZK53 Activates ClpP to Arrest Lung Cancer Growth
2026-09-15
The reference study identifies ZK53 as a selective activator of human mitochondrial ClpP and shows that it suppresses lung squamous cell carcinoma through mitochondrial proteostasis failure, impaired oxidative phosphorylation, and ATM-linked DNA damage signaling. Its combination of structural, cellular, mechanistic, and animal-model evidence provides a framework for studying cell cycle arrest induction through mitochondrial stress.
-
Coumestrol, Ferroptosis, and RA-FLS Mechanisms
2026-09-14
A 2026 study identifies a TRIM3–PMAIP1 regulatory axis through which Coumestrol promotes ferroptosis in rheumatoid arthritis fibroblast-like synoviocytes. Its layered cellular, inflammatory, mitochondrial, and gene-regulatory assays provide a mechanistic framework for studying how synoviocyte death may limit pathological proliferation and cytokine production.
-
AI-10-49: A RUNX1-Restoring AML Research Tool
2026-09-14
AI-10-49 is a selective CBFβ-SMMHC inhibitor for dissecting inv(16) acute myeloid leukemia biology. This article presents a causal assay framework that connects fusion-protein disruption with RUNX1 reactivation, N-MYC/eIF4G1 signaling, and leukemia phenotypes.
-
PTGER4–HDAC Signaling in Rectal Epithelium
2026-09-13
Anbazhagan et al. connect stromal-cell PGE2 production with PTGER4-dependent changes in class IIa HDAC phosphorylation and SPINK4 expression in rectal epithelial organoids. The study provides a mechanistic framework for interpreting epithelial repair signals while highlighting the need to preserve phosphorylation states during protein-based validation.
-
GRA12 and Cross-Strain Toxoplasma Virulence
2026-09-12
The reference study uses pooled in vivo CRISPR–Cas9 screening to identify virulence factors that remain important across diverse Toxoplasma gondii strains and mouse backgrounds. GRA12 emerged as a central dense-granule effector whose loss destabilized the parasitophorous vacuole, increased host-cell necrosis, and revealed a conserved mechanism shared with related coccidian parasites.
-
PEP Restricts cGAS Inflammation in Healthy Aging
2026-09-11
A 2026 Nature Aging study identifies phosphoenolpyruvate (PEP) as an endogenous metabolic brake on cGAS–STING-driven inflammaging. By combining longitudinal profiling, plasma-transfer experiments, metabolic perturbation, biochemical analysis, and disease modeling, the authors connect glycolytic state with healthy aging and neuroinflammation.
-
E-64d as a Causal Probe of Lysoptosis
2026-09-11
E-64d is a membrane-permeable cysteine protease inhibitor that can help distinguish calpain- and cathepsin-dependent cell death from downstream lysosomal damage. This article presents a causal assay framework grounded in lysoptosis research, with practical guidance for apoptosis, platelet, seizure-model, and cancer research.
-
SARS-CoV-2 NSP15 Inhibitors: Thymopentin and Oleuropein
2026-09-10
A 2021 structure-based screening study identified thymopentin and oleuropein as the most favorable predicted binders of SARS-CoV-2 NSP15, an endoribonuclease involved in viral immune evasion. Molecular dynamics simulations supported the persistence of both complexes, but biochemical, cellular, and in vivo validation remain necessary before these compounds can be considered antiviral inhibitors.
-
Risedronate Sodium: Applied Research Workflows
2026-09-10
Risedronate Sodium combines FPPS pathway activity with flexible delivery options for bone, pulmonary, and formulation research. This guide translates published nanotransferosome–microneedle results into practical cell, ex vivo, and in vivo workflows with troubleshooting checkpoints.
-
Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO)
2026-09-09
Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) helps limit proteolytic loss during cell or tissue lysis, with compatibility advantages for workflows that require divalent cations. Use it at least 200-fold diluted, but do not treat it as a metal chelator or assume compatibility with DMSO-sensitive assays without testing.
-
Alfuzosin Hydrochloride Assay Guide
2026-09-09
A scenario-based guide to using Alfuzosin Hydrochloride (SKU A5173) in cell viability, proliferation, and cytotoxicity workflows. It addresses solvent compatibility, endpoint controls, data interpretation, and practical criteria for selecting a reliable research-grade source.